Coordination of Abilify lawsuits continues to progress as the judge overseeing the centralization has now made plans to streamline the filing process. Now, plaintiffs may use a Short Form Complaint to file their lawsuits directly into the multidistrict litigation in Florida, saving time and transfers... Read More

The use of Paxil (paroxetine) by pregnant women during their first trimester has again been linked to birth defects in their children, according to a recent review of previous scholarly studies on the subject. Although the antidepressant is considered relatively safe, it nevertheless comes with... Read More

Another study has found a compelling association between use of antidepressants during pregnancy and autism in children born to those women. The study found that women who used these drugs during the second half of their pregnancies increased the risk that their unborn children would eventually... Read More

  On Dec. 2, defendant Pfizer scored a notable victory in the ongoing Zoloft multidistrict litigation pending in the U.S. District Court for the Eastern District of Pennsylvania. Judge Cynthia M. Rufe issued an order that the opinion of Dr. Nicholas Jewell Ph.D. — the... Read More

The first Zoloft lawsuit filed in federal court has been scheduled for an early trial date in March 2016. This lawsuit, known as a bellwether case, is essentially a test case that allows all parties involved with the multidistrict litigation (MDL) to gauge how juries... Read More

The U.S. Food and Drug Administration (FDA) has asked Pfizer, Inc. to change the safety warnings on its Zoloft packaging. If Pfizer complies, the label change will be Pfizer’s first acknowledgement that a woman’s prenatal use of the antidepressant may cause heart defects in newborns.... Read More

In 2001, the publication of Study 329 prompted a 36 percent increase in prescriptions for Paxil (paroxetine), as it led healthcare providers to believe that Paxil was safe for use in adolescents. Yet, a reassessment of the same clinical data questions the accuracy of the... Read More

A recent analysis published in JAMA Internal Medicine shows that 10 percent of cases where a drug causes severe harm to patients are not reported to the FDA within the specified 15-day time period. This lag time in reporting serious adverse events endangers lives needlessly,... Read More